Strides Pharma Science (NSE:STAR) Tax Provision: ₹-942 Mil (TTM As of Mar. 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
74 GF Score
Price ₹1,082.60
GF Value ₹779.55
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Tax Provision?

Strides Pharma Science NSE:STAR +0.61% 74 Tax Provision is ₹-942 Mil as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 74/100 and a GF Value™ of ₹779.55 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Strides Pharma Science's tax provision for the three months ended in Mar. 2026 was ₹-188 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-942 Mil.

Strides Pharma Science Tax Provision Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Tax Provision Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,782.63 553.01 -291.12 -775.16 -941.86

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -207.59 -164.50 -215.93 -373.53 -187.70
NSE:STAR
74GF Score
Strides Pharma Science Ltd NSE:STAR
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-942 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ₹-942 Mil mean?
Strides Pharma Science (NSE:STAR) has a Tax Provision of ₹-942 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's Tax Provision too high?
Strides Pharma Science's current Tax Provision is ₹-942 Mil. Overall, Strides Pharma Science has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Tax Provision compare to ZTS and UTHR?
Strides Pharma Science's Tax Provision of ₹-942 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Tax Provision is ₹-942 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹779.55, compared to a current price of ₹1,082.60 — trading 38.9% above its estimated fair value. The current Tax Provision is ₹-942 Mil. Strides Pharma Science's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Tax Provision is ₹-942 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,082.60 is trading 38.9% above its estimated GF Value™ of ₹779.55. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Tax Provision: ₹-942 Mil
  • GF Value™: ₹779.55 vs. price of ₹1,082.60 (38.9% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
74GF Score

Get the complete analysis for NSE:STAR

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,082.60
Price
₹779.55
GF Value